Published in Vaccine Weekly, April 7th, 2004
A 6-month phase I Small Business Innovation Research (SBIR) grant of approximately $300,000 will partially fund preclinical safety and toxicity evaluation of the CMV vaccine in support of the company's planned phase I human trial.
An 18-month research grant of approximately $700,000 will partially fund novel assays to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly